Clinical Trial Update: Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Gefitinib for recurrent or metastatic esophageal or gastroesophageal junction cancer has completed, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-03-16